文献速递MDS 与骨髓增殖性肿瘤

泛PIM抑制剂INCB053914与芦可替尼在MPN模型中显示强效协同作用

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
PubMed 文献 · Blood Adv · 2019-01-01

本研究探讨泛PIM抑制剂INCB053914联合JAK1/2抑制剂芦可替尼在JAK2驱动的骨髓增殖性肿瘤(MPN)模型中的疗效。体外和体内实验表明,INCB053914与芦可替尼协同抑制细胞生长并诱导凋亡,低纳摩尔浓度即可增强芦可替尼对原代MPN患者细胞的抑制作用,并拮抗体内持续性骨髓增殖。结果支持该联合方案在MPN患者中的临床测试。

要点

  • INCB053914与芦可替尼在JAK2驱动MPN模型中协同抑制生长并诱导凋亡。
  • 低纳摩尔INCB053914增强芦可替尼对原代MPN患者细胞的疗效。
  • INCB053914拮抗体内芦可替尼持续性骨髓增殖,支持临床联合测试。

核心结论

  • INCB053914与芦可替尼联合在MPN模型中显示协同作用,可能对MPN患者有效。

研究设计与样本

  • 研究采用体外和体内MPN模型,包括JAK2驱动的MPN细胞系和原代MPN患者细胞。

主要发现

  • INCB053914与芦可替尼协同抑制JAK2驱动MPN模型中的细胞生长并诱导凋亡。
  • 低纳摩尔浓度的INCB053914增强芦可替尼抑制原代MPN患者细胞肿瘤性生长的效果。
  • INCB053914在体内拮抗芦可替尼持续性的骨髓增殖。

临床怎么用

  • 支持在MPN患者中开展INCB053914联合芦可替尼的临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden in MPN patients, underscoring the need for improved therapeutic strategies. Members of the PIM family of serine/threonine kinases promote cellular proliferation by regulating a variety of cellular processes, including protein synthesis and the balance of signaling that regulates apoptosis. Overexpression of PIM family members is oncogenic, exemplified by their ability to induce lymphomas in collaboration with c-Myc. Thus, PIM kinases are potential therapeutic targets for several malignancies such as solid tumors and blood cancers. We and others have shown that PIM inhibitors augment the efficacy of JAK2 inhibitors by using in vitro models of MPNs. Here we report that the recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models. INCB053914 synergizes with ruxolitinib to inhibit cell growth in JAK2-driven MPN models and induce apoptosis. Significantly, low nanomolar INCB053914 enhances the efficacy of ruxolitinib to inhibit the neoplastic growth of primary MPN patient cells, and INCB053914 antagonizes ruxolitinib persistent myeloproliferation in vivo. These findings support the notion that INCB053914, which is currently in clinical trials in patients with advanced hematologic malignancies, in combination with ruxolitinib may be effective in MPN patients, and they support the clinical testing of this combination in MPN patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mazzacurati L, Collins RJ, Pandey G, et al. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Adv. 2019. PMID: 31725895. doi:10.1182/bloodadvances.2019000260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。